When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases and a product-by-product exclusive ...

According to Novo Nordisk, in March 2022, the FDA found issues with sterility at a compounding pharmacy that had had five ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

The PEGylated Proteins Market is primarily driven by the growing demand for effective drug delivery systems, particularly in the treatment of chronic diseases such as cancer, hepatitis, and rheumatoid ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...